GLP-1 and HRT: What changes when you take both

If you're in midlife, you may be weighing two treatments at once. One is hormone replacement therapy (HRT) for menopause symptoms. The other is a GLP-1 (glucagon-like peptide-1) medication for weight, often prescribed by a different clinician.

The short answer on GLP-1 and HRT: they're generally used together, and early research is encouraging. But a few practical details matter, especially if you take your hormones by mouth.

A quick note on terms. Semaglutide (Wegovy®, Ozempic®) is a GLP-1 agonist, while tirzepatide (Zepbound®, Mounjaro®) is a dual agonist that acts on both GLP-1 and GIP receptors. This guide covers both medication types.

Below: what the research says (and doesn't), how these medications may affect oral hormones, why contraception matters, and how to coordinate care. Midlife hormone shifts are real biology, and a menopause weight loss plan works best when it accounts for them.

Key takeaways

• GLP-1 and dual-agonist medications are commonly used with HRT, and no direct interaction between them is expected.
• Two observational Mayo Clinic studies link HRT use with greater weight loss on semaglutide and tirzepatide, but they can't prove HRT caused it.
• These medications slow digestion, so UK menopause guidance suggests oral estrogen and oral progesterone may be absorbed less, and non-oral options may be preferable.
• Tirzepatide can make oral contraceptives less effective after you start and after each dose increase, which matters in perimenopause.
• Tell every prescriber about every medication, and report any new or unexpected bleeding.

Can you take a GLP-1 and HRT together?

For many people, yes. GLP-1 and dual-agonist medications are often prescribed alongside HRT, and no direct interaction between them is expected. The practical questions are narrower: how well hormones taken by mouth are absorbed, and whether birth control still works as intended.

The two treatments do different jobs. The North American Menopause Society (now The Menopause Society) 2022 position statement calls hormone therapy the most effective treatment for hot flashes and night sweats. It has also been shown to prevent bone loss and fracture.

HRT isn't a weight-loss medication. Weight medications like tirzepatide, by contrast, are labeled for chronic weight management alongside a reduced-calorie diet and more physical activity, per the Zepbound® FDA label.

Standard screening still applies when you add a weight medication. The Zepbound® and Wegovy® labels carry a boxed warning about thyroid C-cell tumors seen in rodents, though human relevance is unknown. These medications aren't used if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

GLP-1s are a safe option for many people. Before prescribing, a Found-affiliated clinician reviews your full health history and medication list, including any hormones you take.

What the research says about combining HRT and GLP-1s

The evidence on combining the two is promising but modest: two small observational studies from Mayo Clinic, neither able to show cause and effect.

The semaglutide study

A 2024 study in the journal Menopause looked back at the medical records of postmenopausal women who took semaglutide for overweight or obesity. Researchers compared 16 women using hormone therapy with 90 women who weren't.

At 12 months, the hormone therapy group had lost about 16% of their total body weight vs. 12% in the group without it. The researchers described hormone therapy use as "associated with an improved weight loss response," and the link held after adjusting for other factors.

Still, 16 women is a very small group. Because the study looked backward at existing records, it can show an association, not proof that HRT drove the extra loss.

The tirzepatide study

A Mayo Clinic observational study published in January 2026 in The Lancet Obstetrics, Gynaecology, & Women's Health asked a similar question about tirzepatide. Researchers reviewed data from 120 postmenopausal women with overweight or obesity who took tirzepatide for 12 or more months.

Women using hormone therapy lost about 35% more weight than women taking tirzepatide alone. That's roughly 19% vs. 14% of body weight (as reported in news coverage of the study).

The research team was clear about the limits. "Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss," they said in a Mayo Clinic news release.

What these studies can't tell you yet

Women who use hormone therapy may differ from those who don't in ways that affect weight. The Mayo researchers suggested better sleep and symptom relief, or healthier habits at the start, could explain some of the gap. A randomized trial is planned to test the question directly.

Until then, the evidence doesn't support starting HRT just to boost weight loss. If hot flashes or poor sleep are wearing you down, though, treating them may make the rest of your plan easier to stick with. Found's guide to HRT and GLP-1 for weight loss covers how the two may complement each other.

Why oral HRT may need a second look on a GLP-1

GLP-1 and dual-agonist medications slow how quickly your stomach empties, a process called gastric emptying. That can change how medications taken by mouth are absorbed. The Zepbound® label notes this delay is largest after the first dose and lessens over time.

Two UK sources from 2025 address what this could mean for HRT: NHS Lothian guidance and a British Menopause Society clinician tool. Both say oral estrogen and oral progestogens could be absorbed less. Both also say direct evidence is lacking, so the advice is precautionary.

This guidance comes from the UK, and US prescribers may approach it differently, which makes it even more useful to raise the question with your prescriber directly.

With estrogen taken by mouth, NHS Lothian says lower absorption could bring back menopause symptoms or cause unscheduled bleeding, but it doesn't expect clinical harm. The British Menopause Society suggests considering a switch to transdermal estrogen, which is absorbed through the skin from a patch, gel, or spray. Both UK sources note transdermal estrogen is already often preferred at a higher BMI because of blood clot risk.

Progesterone taken by mouth is the bigger concern if you have a uterus. In HRT, a progestogen (progesterone or a similar hormone) protects the uterine lining from overgrowth, called endometrial hyperplasia. Reduced absorption could, in theory, weaken that protection.

Non-oral progestogen options aren't expected to be affected. These include a levonorgestrel hormonal IUD, a combined estrogen-progestogen patch, or progesterone used vaginally (an off-label use). Based on expert opinion, the British Menopause Society calls the hormonal IUD likely the most comprehensive option.

None of this means changing anything on your own. Ask your HRT prescriber for a review when you start a GLP-1 or dual-agonist medication, and again when your dose goes up.

Bleeding is a signal worth reporting

Unscheduled bleeding while you're on HRT and a GLP-1 or dual-agonist medication deserves a call to your clinician. It could relate to lower hormone absorption, but it's not something to assume is just a medication side effect.

Your clinician will want to evaluate it, especially if you have a uterus. Reporting it early gives your care team time to check your lining protection and adjust your plan if needed.

Birth control matters in perimenopause

Perimenopause isn't menopause, and pregnancy can still happen during the transition. If you use oral contraceptives, whether for pregnancy prevention or symptom control, your weight medication matters too.

Tirzepatide (Zepbound®, Mounjaro®) has the clearest guidance. The Zepbound® FDA label advises switching to a non-oral contraceptive or adding a barrier method, such as condoms, for four weeks after starting. The same applies for four weeks after each dose increase, and non-oral hormonal contraceptives shouldn't be affected.

Semaglutide is different. A January 2025 statement from the UK's Faculty of Sexual and Reproductive Healthcare (FSRH) says there's no need to add a barrier method with semaglutide. The FSRH also notes that evidence for all of these medications comes from limited pharmacokinetic studies, which measure how a medication moves through the body.

Pregnancy planning matters, too. The Zepbound® and Wegovy® labels say to stop the medication when pregnancy is recognized. The Wegovy® label says to stop at least two months before a planned pregnancy, and the FSRH suggests one month for tirzepatide.

One distinction is easy to miss: birth control taken by mouth isn't the same as HRT, even though both can be oral hormones. The tirzepatide label guidance addresses oral contraceptives, not HRT.

If you're in perimenopause and want a gentler start, Found's microdosing program is designed for people in hormonal transition. A Found clinician reviews your health history first and prescribes medication only if it's clinically appropriate.

Protecting muscle, bone, and results over time

Midlife changes body composition, even when the scale doesn't move much. A 2019 analysis from the Study of Women's Health Across the Nation (SWAN) appeared in JCI Insight. It found the rate of fat gain doubled at the start of the menopause transition, while lean mass declined.

Scale weight, meanwhile, climbed steadily without speeding up. So the number on the scale may not tell the whole story.

Weight loss on GLP-1 and dual-agonist medications includes some lean mass, but fat mass drops more. In a body composition substudy of the STEP 1 trial (New England Journal of Medicine, 2021), lean mass decreased in absolute terms with semaglutide. Fat mass dropped more, so the share of the body made up of lean mass rose.

The same Zepbound® prescribing information similarly reports greater fat loss than lean loss with tirzepatide.

A few habits are worth discussing with your care team: enough protein spread across meals, strength training, and sleep. Found's lifestyle guidance and coaching cover nutrition, movement, and sleep, so medication stays one tool within a bigger plan. Since hormone therapy helps prevent bone loss, your HRT plan belongs in that conversation, too.

Stopping matters as well. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide and the trial's lifestyle program. If you're considering a change, plan it with your clinician.

Questions to bring to your clinicians

Your HRT prescriber and your weight care clinician may be two different people. These questions can help both see the full picture:

• Does your HRT prescriber know you're starting, or changing the dose of, a GLP-1 or dual-agonist medication?
• Is your estrogen or progestogen taken by mouth, and would a patch, gel, or IUD make more sense now?
• Do you have a uterus, and is your lining protected?
• Do you need backup contraception, and for how long?
• What's the plan if you have unexpected bleeding or your hot flashes return?
• What's your plan for protein, strength training, and side effects?
• Will every clinician know about both medications before a procedure that involves anesthesia or sedation?

That last question matters because the Zepbound® prescribing information (linked above) lists a risk of aspiration (inhaling stomach contents) during anesthesia or deep sedation.

Found clinicians focus on your weight care and can coordinate with the clinician who manages your HRT. You can share your HRT details during your metabolic assessment, so your plan reflects them from the start.

FAQs about GLP-1 and HRT

Is it safe to take GLP-1 while on HRT?

For many people, yes, and the key safety step is making sure both prescribers know about both medications. Label screening for personal or family thyroid cancer history still applies.

Which is better for weight loss, HRT or GLP-1?

GLP-1 and dual-agonist medications treat weight, while HRT treats menopause symptoms and helps protect bone. HRT may support your plan by easing symptoms, but it isn't a weight-loss treatment.

Is it safe to take progesterone and GLP-1 together?

They're commonly used together. If you have a uterus and take progesterone by mouth, ask your prescriber about non-oral options.

Do GLP-1s lower estrogen?

These medications aren't known to directly change hormone production. If symptoms return on oral estrogen, UK guidance points to reduced absorption as one possible reason.

Will HRT make my belly fat go away?

The Menopause Society's (formerly NAMS) 2022 position statement notes the menopause transition shifts fat toward the midsection, but women using hormone therapy didn't show observable differences in weight or body fat gain (in relatively small studies). HRT treats symptoms, while fat loss comes from your broader weight care plan.

Does tirzepatide affect birth control?

Yes, it can make oral contraceptives less effective for four weeks after starting and after each dose increase. Non-oral methods aren't expected to be affected.

A weight care plan that accounts for your hormones

Midlife weight changes are biological, not a failure of willpower. HRT and GLP-1 or dual-agonist medications can be part of the same thoughtful plan when the clinicians prescribing them work from the same information.

Found's doctor-designed program pairs clinician-guided medication, if appropriate, with lifestyle support for nutrition, movement, and sleep. Results vary, and your plan can evolve as your hormones do.

Curious how a weight care plan could fit alongside your HRT? Get started.

Found is among the largest medically-supported telehealth weight care platforms in the country, having served more than 250,000 members to date. To discover your MetabolicPrint™ and start your journey with Found, take our quiz. *Individual results may vary.